"Influenza medicine" 0.99 yuan!This bidding pharmaceutical company is still the infusion faucet, the owner's net worth is 8.4 billion

The seventh pharmaceutical concentrated band purchase can be said to be rolled up!

On July 13, the domestic infusion market leader Coron Pharmaceutical announced the results of the 11 products to be won. As a large bid for the previous collection, this time Collenine Pharmaceutical is also one of the most varieties of pharmaceutical companies. Qilu Pharmaceutical and Yangzijiang Pharmaceutical.

The competition in this collection is also fierce, involving a total of 61 drugs, and the average price reduction of drugs is 48%. It is worth mentioning that of the 11 products of Coron Pharmaceutical's winning bid, there are four products with 0 sales in 2021, including "fluid medicine" octhelvir, Hydinininininhinine, horses, horses, and horses. Come to sour analidicinine and Palonohochloride in injection.

The so -called barefoot is not afraid of wearing shoes, Kelun Pharmaceutical has implemented the "price exchange" to the end, especially in the Ausi -Wei price of the "fluid medicine" that is quite intensely regarded as "influenza medicine medicine" in this competition. The Olympic Olympic Veye, who has not yet contributed income, has a bid price of only 1.496 yuan/piece.

Earlier, this generic drug 90 % of the market has been firmly occupied by East Sunshine Company. Its sales are not only far beyond the original research pharmaceutical company Luo Shi, but also the largest Olympic producer in China. According to Mine.com, in 2019, in Chinese public medical institutions and Chinese urban physical pharmacies, Osdim Weirou's total sales exceeded 6.5 billion yuan.

In this Olympic Owner's collection, East Sunshine also bid at the lowest price of 0.99 yuan/piece. From the e -commerce platform, it can be seen that the East Sunshine (75mg/6 capsule) Olydivir (product name: Kewei) costs 77.4 yuan, with an average of 12.9 yuan.

After the collection, the sadness and joy of the pharmaceutical companies are not the same, but the ultimate goal of pursuing profits has not changed. Among them, Koron Pharmaceutical is frequently out of "collection". Among the fifth batch of national collection in 2021, Kellen Pharmaceuticals had a total of 11 products winning, and the number of winning bids was tied for first.

You know, Coron Pharmaceutical was once known as the "King of Infusion" in the A -share market. Since the transformation of generic drugs in 2012, in recent years, it has quickly opened the market and popularity with the collection of collection. The sales amount of pharmaceuticals is 3.251 billion yuan.

The so -called large infusion is an intravenous drip with a capacity of more than 50ml, which is often called "dripping" and "hanging bottle". As of 2021, Kelun Pharmaceutical has 59 varieties of 958 specifications of medical products, of which 130 varieties have a total of 300 specifications of infusion products. In 2021, the infusion sales of Creed Pharmaceuticals reached 4.077 billion bottles, which means that if average, one person has used one person to use his product.

Today, Coron Pharmaceutical and China Resources Shuanghe and Shi Siqi have occupied 70 % of the domestic large infusion markets. Standing at the founder of the "King of Infusion" Coron Pharmaceutical, Liu Jingshen, the founder of Kellen Pharmaceutical, is also a "ruthless man". In 1995, due to the attitude of dissatisfaction with the American boss to Chinese employees, Liu Ring, 44, resigned from the Sino -US joint venture in Sichuan Sichuan. General Manager of Qili Pharmaceutical Co., Ltd.. Kelly Pharmaceutical was established in 1996 after making up 1 million yuan in Dongpin and West.

In 2010, Kelun Pharmaceutical was successfully listed, and the founder of the Liu Herura behind it also realized a leap of wealth. Later, under the leadership of Liu Jingsin, the company opened cross -border and successively entered antibiotics, generic drugs and innovative medicine tracks. Today, 60 % of the company's revenue comes from the infusion business, and 40 % come from non -infusion. In 2021, Coron Pharmaceutical's revenue was 17.277 billion yuan, an increase of 4.94%year -on -year; net profit was 868 million yuan, an increase of 9.7%from 791 million yuan in 2020.

Although the profit of Caren Pharmaceutical in 2021 has recovered, it still has not reached the level of net profit of 1.213 billion yuan in 2018. Sudden performance also caused the stock price of Coren Pharmaceutical to return to the pinnacle of 34.48 yuan/share in 2018. As of the closing of July 13, 2022, the Coron Pharmaceutical Industry reported 19.26 yuan/share, a higher point of 44%, and the market value was about 27.5 billion yuan.

As a typical family -style enterprise, Liu Yuguang, Liu Xianxin's sister, and his brother -in -law Yin Fenggang are all shareholders of the company. His son Liu Sichuan not only acts with his father as a actress, but also the general manager of the company. As of the end of 2021, Liu Ring's family held a total of 30.85%of the company's shares. Based on the latest market value, the Liu Ring family's net worth was 8.4 billion yuan.

(Author ｜ Zeng Jiayi, Editor | Liao Ying)

- END -